Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lantern Pharma Q3 2023 Gaap EPS $(0.29) Beats $(0.45) Estimate

Author: Benzinga Newsdesk | November 08, 2023 05:33pm
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.45) by 35.56 percent. This is a 38.1 percent decrease over losses of $(0.21) per share from the same period last year.

Posted In: LTRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist